Vizora日本語

BrightPath BiotherapeuticsBrightPath Biotherapeutics Co., Ltd.4594東証グロース医薬品FY ending Mar 2025, non-consolidated, J-GAAP

BrightPath Biotherapeutics FY ending Mar 2020 results

BrightPath Biotherapeutics brought in ¥11.3M in revenue.

It lost about ¥16171 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 BrightPath Biotherapeutics sells, how much goes where, and how much is kept.

FY ending Mar 2020
Cost of sales
¥39
SG&A
¥16232
Operating loss
¥16171
Net loss
¥16440

Margin funnel (derived from reported values)Gross margin 60.5% → Operating margin -16171.2% → Net margin -16440.5%

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第21期(2023/04/01－2024/03/31)

    ID S100TP5I2024-06-21Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第19期(令和3年4月1日－令和4年3月31日)

    ID S100PTK62022-12-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第18期(令和2年4月1日－令和3年3月31日)

    ID S100LQ6N2021-06-25Open

Extracted from XBRL: 35 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image